Acute Ischemic Stroke Clinical Trial
Official title:
Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke
Stroke, a personal, familial, and social disaster, is the first cause of acquired
disability, the second cause of dementia, and the third cause of death worldwide. Its
associated socio-economic costs are astronomic. The burden of stroke is likely to increase,
given the aging of the population and the growing incidence of many vascular risk factors.
Therefore, apart from further development of stroke prevention and treatment strategies,
rational and effective tools for diagnosis, monitoring, and follow-up for stroke patients
have potential high long-term clinical and economic consequences.
For neuroradiological work-up, computed tomography (CT) or magnetic resonance imaging (MRI)
are used as gold standard techniques to detect presence or absence, effective state, and
extent of stroke. However, these techniques achieve simply a baseline study of ischemia
occurred and can deliver only a snapshot of brain parenchyma and vessels. Furthermore, their
rapid and actual availability, especially in primary hospitals, and their dynamic
capabilities and predictive values for further infarction are poor with critically ill
patients have to be repeatedly transferred to the scanning unit for each measurement.
Whereas CT examination is associated with x-ray radiation and may miss early detection of
stroke, MRI is associated with higher costs and not generally routinely and around-the clock
available in all the hospitals. Therefore, a simple, fast, repeatable, non-hazardous, and
non-invasive dynamic bedside tool for the detection of acute brain tissue hypoperfusion and
monitoring for potential further infarction or efficacy of thrombolysis either by systemic
intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) or by
selective intraarterial fibrinolysis and mechanical recanalization, both combined with or
without bridging after acute ischemic stroke, is strongly needed.
A promising alternative method of diagnosing stroke represents contrast-enhanced ultrasound
perfusion imaging (UPI). What makes UPI so valuable is the advantage of repeatedly and
non-invasively detecting brain tissue at risk for infarction by dynamic direct brain tissue
perfusion assessment and not by surrogate parameters, like blood flow velocity or vessel
diameter. Because of the possibility to screen and repeatedly measure the state of
perfusion, the chances increase to diagnose and monitor ischemic stroke and to define the
appropriate window for treatment. The perfusion analysis would also allow determination of
treatment results and guidance of rapid and adequate further therapy.
Therefore, the present pilot study in 40 patients is initiated. The objectives of this
observational diagnostic cohort trial are to evaluate feasibility and practicability of
repeated bedside assessments by contrast enhanced UPI in acute ischemic stroke patients and
to assess whether UPI can detect alterations in brain tissue perfusion before and after
recanalising therapy of strokes. Assessment of cerebral perfusion by CT or MRI serves as
reference and its results are compared to UPI data.
Background
Stroke is a personal, familial and social disaster. Apart from development of stroke
prevention and treatment strategies, the mainstay of stroke research remains new-product
development and improvement of current imaging tools for diagnosis, monitoring and follow-up
of stroke patients. For initial neuroradiological work-up, usually computed tomography (CT)
or magnetic resonance imaging (MRI) are used to detect presence or absence, effective state
and extent of stroke. However, their rapid and actual availability, especially in primary
hospitals, and their dynamic capabilities and predictive values for further infarction are
poor. Currently cerebral CT-perfusion (CTP) imaging can be regarded as the gold standard for
assessing tissue hypoperfusion in this setting. It employs, however, both contrast agent and
X-ray exposition and patients have to be repeatedly transferred to the scanning unit for
each measurement. Therefore, a fast, simple, repeatable, non-hazardous and non-invasive
dynamic bedside tool for the detection of acute brain tissue hypoperfusion and monitoring
for potential further infarction or efficacy of thrombolysis after ischemic stroke is
strongly needed.
Socioeconomic importance of stroke Stroke is the first cause of acquired disability, the
second cause of dementia and the third cause of death worldwide, and its associated
socio-economic costs are astronomic. The burden of stroke is likely to increase, given the
aging of the population and the growing incidence of many vascular risk factors. Therefore,
rational and effective diagnostic and therapeutic management in stroke patients has
potential high long-term clinical and economic consequences.
Current standard therapy after acute ischemic stroke According to the cause of stroke and
apart from medical treatment and surgical options in selected cases, the mainstay of
therapeutic management of acute ischemic stroke itself usually remain systemic intravenous
thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) or selective
intraarterial fibrinolysis and mechanical recanalization, both with or without bridging
(combined intravenous and intraarterial thrombolysis). In this regard, reperfusion therapy
is the only proven treatment for acute ischemic stroke.
Current problems in diagnosis and monitoring of stroke patients At present, CT and MRI are
usually applied for diagnosis and follow-up of stroke. However, both CT and MRI achieve
simply a baseline study of ischemia occurred and can deliver only a snapshot of brain
parenchyma and vessels. Furthermore, whereas CT examination is associated with x-ray
radiation and may miss early detection of stroke, MRI is associated with higher costs and is
not generally routinely and around-the clock available in all the hospitals. Both imaging
methods require transportation and intensive care of the often critically ill patients to
the scanning unit for each measurement.
There is unanimous agreement about the need for a bedside assessment of the status of tissue
perfusion. Invasive cerebral angiography is indicated in cases of further evaluation of
stroke causes and intended endovascular therapy.
Potential of ultrasound perfusion imaging (UPI) What makes contrast enhanced UPI so valuable
is the possibility to repeatedly and non-invasively detect brain tissue at risk for
infarction by direct brain tissue perfusion assessment and not by surrogate parameters, like
blood flow velocity or vessel diameter. Because of the possibility to screen and repeatedly
measure the state of perfusion, the chances increase to diagnose and monitor ischemic stroke
and to define the appropriate window for treatment. The perfusion analysis would also allow
determination of treatment results and guidance of rapid and adequate further therapy.
Objective
The objective of the present study is to assess whether cerebral hypoperfusion can be
detected by ultrasound perfusion imaging (UPI) before and after treatment of acute ischemic
stroke.
Methods
Patients with acute middle cerebral artery (MCA) territory ischemic stroke are evaluated for
potential thrombolysis/thrombectomy according to the Bernese neurologic stroke algorithm. An
experienced neurosonographer performs contrast-enhanced ultrasound perfusion imaging (UPI)
after prospective study enrollment and specific stroke CT/MRI with perfusion measurement.
Clinical status is documented by use of the NIHSS on admission /first day after the
intervention. UPI and CT/MRI perfusion data is analyzed. Two different quantification
algorithms, standard versus patient-adjusted, are used. Data is analyzed by descriptive
statistics using the mean, median and standard deviation of the ROIs. Sensitivity and
specificity analyses are calculated using Pearson`s chi-square test. Receiver-operator
characteristic curves are calculated for UPI/perfusion MRI/CT parameters. Pearson
correlation is used to evaluate correlations between absolute values of UPI and MRI TTP
data.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |